<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Grifoni A</submitter><funding>HHS | National Institutes of Health</funding><funding>Bill and Melinda Gates Foundation</funding><pagination>e02133-16</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5375662</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>91(8)</volume><pubmed_abstract>A deletion variant of the dengue virus (DENV) serotype 2 (DENV2) Tonga/74 strain lacking 30 nucleotides from its 3' untranslated region (rDEN2Δ30) has previously been established for use in a controlled human DENV challenge model. To evaluate if this model is appropriate for the derivation of correlates of protection for DENV vaccines on the basis of cellular immunity, we wanted to compare the cellular immune response to this challenge strain to the response induced by natural infection. To achieve this, we predicted HLA class I- and class II-restricted peptides from rDEN2Δ30 and used them in a gamma interferon enzyme-linked immunosorbent spot assay to interrogate CD8+ and CD4+ T cell responses in healthy volunteers infected with rDEN2Δ30. At the level of CD8 responses, vigorous ex vivo re</pubmed_abstract><journal>Journal of virology</journal><pubmed_title>Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.</pubmed_title><pmcid>PMC5375662</pmcid><funding_grant_id>HHSN272200900042C</funding_grant_id><funding_grant_id>HHSN27220140045C</funding_grant_id><funding_grant_id>OPP1104710</funding_grant_id><funding_grant_id>Intramural Research Program</funding_grant_id><pubmed_authors>de Silva AD</pubmed_authors><pubmed_authors>Peters B</pubmed_authors><pubmed_authors>Sette A</pubmed_authors><pubmed_authors>Angelo M</pubmed_authors><pubmed_authors>Phillips E</pubmed_authors><pubmed_authors>Botten J</pubmed_authors><pubmed_authors>Diehl SA</pubmed_authors><pubmed_authors>Paul S</pubmed_authors><pubmed_authors>Sidney J</pubmed_authors><pubmed_authors>Grifoni A</pubmed_authors><pubmed_authors>Kirkpatrick BD</pubmed_authors><pubmed_authors>Whitehead SS</pubmed_authors><pubmed_authors>Weiskopf D</pubmed_authors><pubmed_authors>Mallal S</pubmed_authors><pubmed_authors>Boyson J</pubmed_authors><pubmed_authors>Durbin AP</pubmed_authors></additional><is_claimable>false</is_claimable><name>Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.</name><description>A deletion variant of the dengue virus (DENV) serotype 2 (DENV2) Tonga/74 strain lacking 30 nucleotides from its 3' untranslated region (rDEN2Δ30) has previously been established for use in a controlled human DENV challenge model. To evaluate if this model is appropriate for the derivation of correlates of protection for DENV vaccines on the basis of cellular immunity, we wanted to compare the cellular immune response to this challenge strain to the response induced by natural infection. To achieve this, we predicted HLA class I- and class II-restricted peptides from rDEN2Δ30 and used them in a gamma interferon enzyme-linked immunosorbent spot assay to interrogate CD8+ and CD4+ T cell responses in healthy volunteers infected with rDEN2Δ30. At the level of CD8 responses, vigorous ex vivo re</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Apr</publication><modification>2025-04-05T11:25:52.12Z</modification><creation>2019-03-27T02:40:03Z</creation></dates><accession>S-EPMC5375662</accession><cross_references><pubmed>28148797</pubmed><doi>10.1128/JVI.02133-16</doi><doi>10.1128/jvi.02133-16</doi></cross_references></HashMap>